芦可替尼治疗激素难治性急性GVHD的2期试验
这项多中心开放标签2期研究纳入71例激素难治性急性GVHD患者,接受芦可替尼5mg每日两次联合糖皮质激素治疗。第28天总缓解率为54.9%(95%CI 42.7%-66.8%),完全缓解率26.8%,中位缓解持续时间345天,6个月总生存估计51.0%。
要点
- 芦可替尼对激素难治性急性GVHD产生持久缓解,第28天ORR 54.9%。
- 缓解见于皮肤、上消化道、下消化道和肝脏,中位DOR 345天。
- 常见不良事件为贫血、血小板减少、低钾血症、中性粒细胞减少和外周水肿。
核心结论
- 芦可替尼在激素难治性急性GVHD中产生持久缓解和令人鼓舞的生存,优于历史数据。
研究设计与样本
- 多中心、开放标签、2期试验(NCT02953678),71例≥12岁II-IV级激素难治性急性GVHD患者接受芦可替尼5mg每日两次联合糖皮质激素。
主要发现
- 第28天总缓解率54.9%(95%CI 42.7%-66.8%),完全缓解率26.8%。
- 任意时间最佳总缓解率73.2%,完全缓解率56.3%。
- 中位缓解持续时间345天,6个月总生存估计51.0%。
- 第28天43例接受芦可替尼联合糖皮质激素的患者中24例(55.8%)激素剂量较基线减少≥50%。
关键数值与推荐
- 缓解率:皮肤61.1%,上消化道45.5%,下消化道46.0%,肝脏26.7%。
- 常见治疗中出现的不良事件:贫血64.8%、血小板减少62.0%、低钾血症49.3%、中性粒细胞减少47.9%、外周水肿45.1%。
临床怎么用
- 芦可替尼联合糖皮质激素可用于激素难治性急性GVHD,需监测血细胞减少和电解质紊乱。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients who develop steroid-refractory acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation have poor prognosis, highlighting an unmet therapeutic need. In this open-label phase 2 study (ClinicalTrials.gov identifier: NCT02953678), patients aged at least 12 years with grades II to IV steroid-refractory aGVHD were eligible to receive ruxolitinib orally, starting at 5 mg twice daily plus corticosteroids, until treatment failure, unacceptable toxicity, or death. The primary end point was overall response rate (ORR) at day 28; the key secondary end point was duration of response (DOR) at 6 months. As of 2 July 2018, 71 patients received at least 1 dose of ruxolitinib. Forty-eight of those patients (67.6%) had grade III/IV aGVHD at enrollment. At day 28, 39 patients (54.9%; 95% confidence interval, 42.7%-66.8%) had an overall response, including 19 (26.8%) with complete responses. Best ORR at any time was 73.2% (complete response, 56.3%). Responses were observed across skin (61.1%), upper (45.5%) and lower (46.0%) gastrointestinal tract, and liver (26.7%). Median DOR was 345 days. Overall survival estimate at 6 months was 51.0%. At day 28, 24 (55.8%) of 43 patients receiving ruxolitinib and corticosteroids had a 50% or greater corticosteroid dose reduction from baseline. The most common treatment-emergent adverse events were anemia (64.8%), thrombocytopenia (62.0%), hypokalemia (49.3%), neutropenia (47.9%), and peripheral edema (45.1%). Ruxolitinib produced durable responses and encouraging survival compared with historical data in patients with steroid-refractory aGVHD who otherwise have dismal outcomes. The safety profile was consistent with expectations for ruxolitinib and this patient population.
引用
- Jagasia M, Perales MA, Schroeder MA, et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020. PMID: 32160294. doi:10.1182/blood.2020004823
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。